ACELLMED

SARS-CoV-2 Tests

SARS-CoV-2 test, antigen (English language) – Sale:

SARS-CoV-2 Test Met. Real Time RT-PCR (English language) – Sale (from 11.10.2021):

Quantitative IgG antibody test – SARS-CoV-2 – new

SARS-CoV-2 Test Met. Real Time RT-PCR

Currently, the following methods are recommended for confirmation of SARS-CoV-2 infection are molecular methods that detect the genetic material of the virus (real time RT PCR).

IgG/IgM – SARS-CoV-2 boxed tests

method: immunochromatography – rapid qualitative test

Serologic diagnosis allows the detection of antibodies and may be of value particularly in persons with asymptomatic or mildly symptomatic infections. The presence of antibodies suggests contact of the patient with the virus and the production of antibodies to it by the infected organism.
This test may be performed prior to vaccination to check serum IgG antibody levels in the individual, and after vaccination to check the body’s immune response to the vaccine (according to vaccine manufacturers, full immunity will develop in most vaccinated persons 7-14 days after the second dose of the vaccine).

Our aim:

The main aim of the Acellmed is to conduct commercial screening of new drugs to determine their safety and efficacy on human cardiac cells. In our research, we apply Nobel Prize awarded technology – induced pluripotential stem cells (iPSC), differentiated into cardiac cells – cardiomyocytes. Thus we create opportunities to test potential drugs directly on cardiomyocytes of patients as well as on those of healthy individuals. Our technology enables us to detect substances capable of correcting cardiomyocytes defects, which are responsible for many heart conditions. It also allows us to monitor and detect the risks of potential drugs (e.g., oncological) that may be too toxic for cardiac cells and therefore, dangerous for patients.

Generation of iPSCs lines

Differentiation of Neural Cells

Differentiation of Cardiomyocytes

Drug Screening in case of cardiotoxicity

One of the principal reasons to suspend ongoing research on new therapies is their cardiotoxicity. Regulations require that novel, and promising therapeutic molecules shall be subjected to the rigoristic toxicity tests using traditional methods in vitro and referential animal models. Those tests, however, do not reflect the reaction of human organism on drugs fully; also, they do not allow on detection of many potentially cardiotoxic substances. Direct application of drugs onto human cardiomyocytes, on the one hand, limits the use of lab animals; on the other – it creates a unique opportunity to select and test proper medications correcting particular cardiomyocytes defects. Directly-applied drugs are, therefore, the base of personalized medicine.

Moreover, Acellmed is developing a technology of “the heart-on-the chip,” based on the use of miniaturized micro-circulation systems which will allow on investigating the interaction between different heart cell types, and in the future – also of other organs.

Production line of iPSC and cardiomyocytes

In its research, Acellmed uses human peripheral blood cells (leucocytes), which effectively reprograms into iPSC; afterward, with high efficiency differentiates them into heart cells – cardiomyocytes. Hence we create iPSC bank cells from patients suffering from heart diseases (e.g., genetic primary and secondary cardiomyopathy) and healthy individuals.

Our customers

Business

Biotechnology, pharmaceutical and cosmetics

Science

Scientists interested in research on IPSC and cells differentiated from iPSC

Healthcare

Health care providers / health care institutions

Our offer

Products

Complete line of iPSC and cardiomyocytes
Conducting complete of generating iPSC and differentiated cel upon the commission of potential researchers interested in thier application

Research services

Research on the safety and effectiveness of potential drugs: comprehensive studies on the toxicity of selected substances – potential oncological drugs
Tests on drug efficacy in correcting cardiomyocytes defects, caused by functional disorder (as a result of mutations or undergoing oncological therapy)

Research on the safety and effectiveness of potenial drugs:

We offer the industry and health care institutions the toxicity studies, including tests on potential cardiotoxicity of the substances suspected to be an environmental threat

Our offer will enable the scientists and companies researching new drugs, on selecting safer substances, reducing unnecessary costs of preclinical trials; it may accelerate the process of introducing new drugs into the market.

Contact

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

I consent to processing of my personal data contained in the above contact form by Acellmed Ltd. with the registered seat in Zabrze, St. M. Curie-Skłodowskiej 10C, 41-800 Zabrze, to contact in connection with the application sent via the contact form. The consent may be withdrawn at any time without affecting the lawfulness of personal data processing, which was made on the basis of the consent granted before its withdrawal.

The controller of the personal data, i.e. the entity deciding on the purposes and methods of their processing, is Acellmed Ltd. with the registered seat in Zabrze (41-800), St. Marii Curie - Skłodowskiej 10c, hereinafter referred to as "Acellmed". The contact details of the data protection officer are: iod@acellmed.pl.

Acellmed collects and processes the following personal data: full name and contact details, including telephone number and e-mail address.

Personal data are processed for the purpose of contact by using a telephone number or e-mail address in order to e.g. confirm the visit, cancel the date of the visit or surgery, inform about the possibility of receiving the test result, which is the legitimate interest of Acellmed and patient service (legal basis for data processing: Article 6 paragraph 1 item b GDPR, Article 6 paragraph 1 item f GDPR). The period of storage of personal data is the period of storage of medical documentation resulting from legal provisions.

Personal data are also processed for the purpose of contact in connection with the question/application submitted via the contact form, based on the consent given to processing of data pursuant to Article 6 paragraph 1 item a GDPR for the period necessary to respond to the application and handle correspondence/conversations related to the application, however, not longer than until the withdraw of the consent to processing of personal data.

In addition, Acellmed shall have the right to process data on the basis of a legitimate interest, including research and analysis, and for marketing purposes (legal basis for processing: Article 6 paragraph 1 item f GDPR, Article 6 paragraph 1 item a GDPR, Article 10 paragraph 2 of the Act on the provision of electronic services, Article 172 of the Telecommunications Law).

The data will be processed for the period necessary to achieve the purpose but not longer than until objecting to processing of personal data for this purpose or withdrawal of the consent.

Access to the personal data may be given to Acellmed's employees and associates authorized to process the personal data and entities entrusted with processing of personal data by Acellmed, including a provider of technical and organizational services. Other entities, persons or bodies - to the extent and on the terms specified by law.

Please be advised that providing personal data contained in the form is voluntary but necessary to complete the registration.

Acellmed is allowed to transfer personal data to countries outside the European Economic Area and international organizations, which is related to the scope of business and co-operation with various entities. Acellmed ensures that the data will be transferred to countries for which the European Commission has issued decisions on their compliance with an adequate level of protection of personal data and/or in compliance with all legal requirements, including on the basis of an appropriate agreement containing data protection clauses adopted by the European Commission, ensuring an appropriate way to secure personal data being transferred.

In connection with processing of personal data, you have the right to access your personal data, the right to rectify your personal data, the right to request the deletion of data, the right to request the restriction of data processing, the right to transfer data, the right to raise objections and the right to lodge a complaint with the supervisory authority.

No automated decisions (non-human decisions) will be made against your personal data, including your data will not be subject to automated profiling.

Adres

ACELLMED Ltd.
St. M. Skłodowskiej-Curie 10c
41-800 Zabrze, Poland
biuro@acellmed.pl